Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Longitudinal peripheral blood multi-omic profiling in seropositive individuals identifies immune endotypes and predictive models for future rheumatoid arthritis conversion.

medRxiv : the preprint server for health sciences·2026

Same author

Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.

RMD open·2025

Same author

Greater HIV Viral Load Suppression in Patients Using an Integrated Health System Specialty Pharmacy.

Journal of pharmacy practice·2025

Same author

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2025

Same author

A report of the safety of prophylactic spinal fluid drainage in open and endovascular thoracic and thoracoabdominal aortic aneurysm patients.

Journal of vascular surgery·2025

Same author

A new education agenda based on The International Science and Evidence Based Education Assessment.

NPJ science of learning·2025

Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026

Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026

Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026

Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026

Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026

Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 27, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Gadolinium-Induced Fibrosis.

Derrick J Todd^1,2, Jonathan Kay³

¹Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115.

Annual Review of Medicine

|January 16, 2016

Summary

This summary is machine-generated.

Gadolinium-based contrast agents (GBCAs) are linked to nephrogenic systemic fibrosis (NSF) in patients with kidney disease. Avoiding high-risk GBCAs has nearly eliminated new NSF cases, a condition now proposed to be renamed gadolinium-induced fibrosis (GIF).

Keywords:

Gd chronic kidney disease fibrosing disorders gadolinium-based contrast agents magnetic resonance imaging nephrogenic systemic fibrosis

More Related Videos

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications

Published on: April 28, 2015

Related Experiment Videos

Last Updated: Mar 27, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications

Published on: April 28, 2015

Area of Science:

Nephrology
Radiology
Toxicology

Background:

Gadolinium-based contrast agents (GBCAs) were initially considered safe for patients with renal disease.
However, a strong association emerged between GBCA use and nephrogenic systemic fibrosis (NSF), a severe fibrosing disorder.
NSF predominantly affects individuals with advanced renal dysfunction.

Purpose of the Study:

To provide a historical overview of nephrogenic systemic fibrosis (NSF).
To examine the association between GBCA exposure and NSF.
To propose renaming NSF to gadolinium-induced fibrosis (GIF) to better reflect the causative agent.

Main Methods:

Historical review of clinical data and scientific literature.
Analysis of the temporal relationship between GBCA introduction/restriction and NSF incidence.
Evaluation of evidence supporting a causal link between GBCAs and NSF.

Main Results:

NSF emerged following the introduction of certain GBCAs and declined sharply after their restriction in patients with renal disease.
Strong evidence supports a causative relationship between specific GBCA exposure and NSF.
The proposed name, gadolinium-induced fibrosis (GIF), accurately reflects the disease etiology.

Conclusions:

Use of high-risk GBCAs, like gadodiamide, should be avoided in patients with renal disease.
Restriction of GBCA use in this population has led to the near elimination of new NSF cases.
Emerging antifibrotic therapies may offer future treatment options for patients with GIF.